Literature DB >> 9093813

Post-translational processing of proopiomelanocortin in the pituitary and in the brain.

M G Castro1, E Morrison.   

Abstract

Proopiomelanocortin (POMC) is a neuropeptide precursor molecule which is translocated to the secretory pathway within neuroendocrine cells. It is cleaved by the action of endopeptidases to yield mature peptides like adrenocorticotrophic hormone (ACTH), beta-lipotrophin (beta-LPH), beta-endorphin. In this review we present evidence on the cleavage specificities and structure of endoproteases which cleave neuropeptide precursors at pairs of basic amino acids and on the identity and mode of action of exopeptidases. This information is derived from cloning of their corresponding cDNAs and subsequent expression within neuroendocrine cells; and also from biochemical studies. We discuss the intracellular targeting and sorting mechanisms of POMC within neuroendocrine cells. We also examine the tissue-specific post-translational processing of POMC within the anterior and intermediate lobes of the pituitary gland and within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093813     DOI: 10.1615/critrevneurobiol.v11.i1.30

Source DB:  PubMed          Journal:  Crit Rev Neurobiol        ISSN: 0892-0915


  36 in total

1.  Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents.

Authors:  Philippe Zizzari; Romaine Longchamps; Jacques Epelbaum; Marie Thérèse Bluet-Pajot
Journal:  Endocrinology       Date:  2007-01-04       Impact factor: 4.736

2.  Phosphodiesterase inhibitor-dependent inverse agonism of agouti-related protein on melanocortin 4 receptor in sea bass (Dicentrarchus labrax).

Authors:  Elisa Sánchez; Vera Cruz Rubio; Darren Thompson; Juriaan Metz; Gert Flik; Glenn L Millhauser; José Miguel Cerdá-Reverter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

Review 3.  Central leptin and ghrelin signalling: comparing and contrasting their mechanisms of action in the brain.

Authors:  Xiaoye Shan; Giles S H Yeo
Journal:  Rev Endocr Metab Disord       Date:  2011-09       Impact factor: 6.514

Review 4.  Mitochondrial dynamics in the central regulation of metabolism.

Authors:  Carole M Nasrallah; Tamas L Horvath
Journal:  Nat Rev Endocrinol       Date:  2014-09-09       Impact factor: 43.330

Review 5.  Participation of the central melanocortin system in metabolic regulation and energy homeostasis.

Authors:  Jin Kwon Jeong; Jae Geun Kim; Byung Ju Lee
Journal:  Cell Mol Life Sci       Date:  2014-06-04       Impact factor: 9.261

Review 6.  Hypothalamic proopiomelanocortin processing and the regulation of energy balance.

Authors:  Sharon L Wardlaw
Journal:  Eur J Pharmacol       Date:  2011-01-03       Impact factor: 4.432

7.  Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.

Authors:  Xitong Dang; Raul Coimbra; Liang Mao; Sonia Podvin; Xue Li; Hua Yu; Todd W Costantini; Xiaorong Zeng; Dana Larocca; Brian P Eliceiri; Andrew Baird
Journal:  Cell Mol Life Sci       Date:  2019-06-12       Impact factor: 9.261

8.  Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130.

Authors:  Aaron J Grossberg; Jarrad M Scarlett; XinXia Zhu; Darren D Bowe; Ayesha K Batra; Theodore P Braun; Daniel L Marks
Journal:  Endocrinology       Date:  2009-12-16       Impact factor: 4.736

9.  Effects of selective modulation of the central melanocortin-3-receptor on food intake and hypothalamic POMC expression.

Authors:  Michelle Lee; Andrea Kim; Irene M Conwell; Victor Hruby; Alexander Mayorov; Minying Cai; Sharon L Wardlaw
Journal:  Peptides       Date:  2007-11-21       Impact factor: 3.750

10.  A functional melanocortin system may be required for chronic CNS-mediated antidiabetic and cardiovascular actions of leptin.

Authors:  Alexandre A da Silva; Jussara M do Carmo; J Nathan Freeman; Lakshmi S Tallam; John E Hall
Journal:  Diabetes       Date:  2009-06-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.